Completed PHASE1 INTERVENTIONAL 3-arm NCT02341391

Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

A Dose-escalating, Single-center, Phase I Clinical Trial to Investigate the Safety and Biological Efficacy of TissueGene-C in Degenerative Arthritis Patients.

Sponsor: Kolon Life Science

Conditions Degenerative Arthritis

Interventions TissueGene-C(High dose) TissueGene-C(Low dose) TissueGene-C(Medium dose)

Updated 8 times since 2017 Last updated: Jul 2, 2018 Started: Feb 28, 2007 Primary completion: Aug 31, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02341391, this PHASE1 trial focuses on Degenerative Arthritis and remains completed. Sponsored by Kolon Life Science, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Dec 2017 [monthly]

Completed PHASE1

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kolon Life Science

Data source: Kolon Life Science

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea